Media Newsroom of

SOM Biotech

SOM Biotech

SOM Biotech Ltd. (www.sombiotech.com) is a biopharmaceutical company founded in 2009 and based in Barcelona, Spain and Boston, US. The company's business strategy is to identify, clinically develop and commercialize drugs to treat rare diseases, based on previously marketed drugs (repositioning) and with special emphasis on the neurological field. The company also collaborates with leading pharmaceutical companies to support them in repurposing portfolios and co-developments around the world, and has an extensive pipeline of products under development ranging from rare diseases (TTR Amyloidosis, Huntington's disease, Glioblastoma and adrenoleukodystrophy) to other therapeutic areas.

SOM Biotech announces a worldwide license of drug SOM0226 for TTR Amyloidosis to Corino Therapeutics

SOM Biotech Ltd (SOM) a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases, today announces an exclusive worldwide license agreement with U.S. based Corino Therapeutics, Inc. (Corino), for the clinical…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login